Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754366 | 0.84 | MAPT (0.46) | MAOBMAOACYSLTR1CTSLMAPT | |
| SCHEMBL751930 | 0.80 | KDM4E (0.57) | MAOBMAOACYSLTR2CYSLTR1MAPT | |
| SCHEMBL751929 | 0.80 | KDM4E (0.57) | MAOBMAOACYSLTR2CYSLTR1MAPT | |
| SCHEMBL765433 | 0.80 | MAOB (0.61) | MAOBMAOACYSLTR2CYSLTR1CTSL | |
| SCHEMBL754648 | 0.79 | MAOB (0.46) | MAOBMAOAGSK3BBACE1NR4A2 | |
| SCHEMBL17907495 | 0.78 | CYSLTR2 (0.56) | MAOBMAOACYSLTR2CYSLTR1MAPT | |
| SCHEMBL17907496 | 0.78 | CYSLTR2 (0.56) | MAOBMAOACYSLTR2CYSLTR1MAPT | |
| SCHEMBL756373 | 0.77 | MAOB (0.49) | MAOBMAOACYSLTR2CYSLTR1CTSL | |
| SCHEMBL754206 | 0.73 | MAOB (0.82) | MAOBMAOANR4A2 | |
| SCHEMBL17907485 | 0.71 | MAOB (0.37) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | MAOB 709/4885MAOA 592/4885CYSLTR2 3946/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | MAOB 900/4885MAOA 729/4885CYSLTR2 4226/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | MAOB 900/4885MAOA 729/4885CYSLTR2 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.